Document is current
Any future updates will be listed below
-
Authors
Brick, Rachelle https://orcid.org/0000-0001-7099-7799
Natori, Akina https://orcid.org/0000-0002-1146-4746
Moreno, Patricia I. https://orcid.org/0000-0002-3083-6461
Molinares, Diana
Koru-Sengul, Tulay https://orcid.org/0000-0003-0974-8405
Penedo, Frank J. https://orcid.org/0000-0002-2780-0417
-
Funding
Funding for this research was provided by:
National Cancer Institute (K01CA258955)
National Cancer Institute (P30CA240139)
- License Information
-
More Information
Article History
Received: 3 October 2022
Accepted: 7 March 2023
First Online: 16 March 2023
Declarations
:
: This study was approved by the University of Miami Institutional Review Board (IRB#20211220) and certifies that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
: This study was part of a performance improvement project within standard of care; therefore and was deemed exempt from institutional review board review, and informed consent was waived.
: Not applicable.
: Dr. Frank J Penedo is a paid consultant for Blue Note Therapeutics. All other authors declares no conflicts of interests.
